Home › NCT06525298

EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors

A Phase 1/2, Open Label Trial to Investigate the Safety, Tolerability, and Preliminary Efficacy of EIS-12656 as Single Agent and in Combination With a Poly-ADP Ribose Polymerase (PARP) Inhibitor or Trastuzumab Deruxtecan (T-DXd), an Antibody Drug Conjugate (ADC), in Participants With Specified Solid Tumors

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Recurrent locally advanced or metastatic solid tumors
* Homologous recombination deficient mutations
* Progressed on at least on prior line of treatment or intolerant to additional effective standard therapy
* Measurable disease (RECIST 1.1 Criteria)
* Adequate organ and bone marrow function
* ECOG Performance Status 0 or 1
* Life expectancy \> 3 months

Exclusion Criteria:

* History or evidence of any clinically relevant gastrointestinal disease
* Radiation therapy within ≤2 weeks
* Significant cardiovascular disease
* Uncontrolled, active, symptomatic brain metastases

About the study

This trial investigates a new drug, EIS-12656, in participants with specified advanced solid tumors carrying pre-specified mutations. The trial consists of a dose escalation part (Phase 1) and a dose expansion part (Phase 2).

What is being tested

• EIS-12656 (drug)
• Olaparib (drug)
• Trastuzumab deruxtecan (drug)

Sponsor: Eisbach Bio GmbH · Participants: 144 · Started: Sep 9, 2024

Contact the study team

• Adrian Schomburg · Phone: +49 17621046886

Official record on ClinicalTrials.gov — NCT06525298

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.